Pre-treatment tumor size impacts on response to nivolumab in head and neck squamous cell carcinoma

Pre-treatment tumor size impacts on response to nivolumab in head and neck squamous cell carcinoma

Baseline tumor size has been reported to be predictive of immune checkpoint inhibitor efficacy in melanoma and lung cancer. We investigated whether pre-treatment tumor size (PTS) is predictive of progression-free survival (PFS) and tumor shrinkage in head and neck squamous cell carcinoma (HNSCC) pat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Auris, nasus, larynx nasus, larynx, 2020-08, Vol.47 (4), p.650-657
Hauptverfasser: Inoue, Hiroto, Yokota, Tomoya, Hamauchi, Satoshi, Onozawa, Yusuke, Kawakami, Takeshi, Shirasu, Hiromichi, Notsu, Akifumi, Yasui, Hirofumi, Onitsuka, Tetsuro
Format: Artikel
Sprache:eng
Schlagworte:
Head and neck squamous cell carcinoma
Nivolumab
Predictive factor
Tumor size
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 657
container_issue 4
container_start_page 650
container_title Auris, nasus, larynx
container_volume 47
creator Inoue, Hiroto
Yokota, Tomoya
Hamauchi, Satoshi
Onozawa, Yusuke
Kawakami, Takeshi
Shirasu, Hiromichi
Notsu, Akifumi
Yasui, Hirofumi
Onitsuka, Tetsuro
description Baseline tumor size has been reported to be predictive of immune checkpoint inhibitor efficacy in melanoma and lung cancer. We investigated whether pre-treatment tumor size (PTS) is predictive of progression-free survival (PFS) and tumor shrinkage in head and neck squamous cell carcinoma (HNSCC) patients treated with nivolumab. We retrospectively assessed 37 patients who had measurable tumor lesions. PTS and post-treatment tumor size were defined as the sum of the size in all measurable lesions. In univariate analysis, PTS below 42 mm, history of radiation therapy, and no use of cetuximab were significantly associated with longer PFS. Among them, small-PTS was an independent predictive factor for PFS in multivariate analysis (hazard ratio: 0.33, p = 0.022). In addition, significantly greater tumor shrinkage was observed for small-PTS than large-PTS (median: −10.0% vs. 23.1%, p = 0.033). PTS may impact the response to nivolumab in HNSCC patients.
doi_str_mv 10.1016/j.anl.2020.01.003
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2353019428</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0385814620300237</els_id><sourcerecordid>2353019428</sourcerecordid><originalsourceid>FETCH-LOGICAL-c443t-b518a1ee9a875dbf98a1f3b19efdb196551531f255cd1be50d6e1220c6cadff43</originalsourceid><addsrcrecordid>eNp9kMFq3DAQhkVoSLabPEAuRcdc7Gosy2vTUwlNWlhoDu1ZyNKYaGtJG0kOJE9fLbvNsZcZBr75mfkIuQFWA4Pu865Wfq4b1rCaQc0YPyMr6DdDBe2m-0BWjPei6qHtLsnHlHasEBs-XJBL3jAuukGsyPgYscoRVXboM82LC5Em-4bUur3SOdHgacS0Dz4hzYF6-xLmxamRWk-fUBmqvKEe9R-anhflwpKoxnmmWkVtfXDqipxPak54fepr8vv-26-779X258OPu6_bSrctz9UooFeAOKh-I8w4DWWa-AgDTqbUTggQHKZGCG1gRMFMh9A0THdamWlq-ZrcHnP3MTwvmLJ0Nh1OUR7LVbLhgjMY2qYvKBxRHUNKESe5j9ap-CqByYNauZNFrTyolQxkEVd2Pp3il9Ghed_457IAX44AlidfLEaZtEWv0diIOksT7H_i_wKl6Irl</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2353019428</pqid></control><display><type>article</type><title>Pre-treatment tumor size impacts on response to nivolumab in head and neck squamous cell carcinoma</title><source>Elsevier ScienceDirect Journals</source><creator>Inoue, Hiroto ; Yokota, Tomoya ; Hamauchi, Satoshi ; Onozawa, Yusuke ; Kawakami, Takeshi ; Shirasu, Hiromichi ; Notsu, Akifumi ; Yasui, Hirofumi ; Onitsuka, Tetsuro</creator><creatorcontrib>Inoue, Hiroto ; Yokota, Tomoya ; Hamauchi, Satoshi ; Onozawa, Yusuke ; Kawakami, Takeshi ; Shirasu, Hiromichi ; Notsu, Akifumi ; Yasui, Hirofumi ; Onitsuka, Tetsuro</creatorcontrib><description>Baseline tumor size has been reported to be predictive of immune checkpoint inhibitor efficacy in melanoma and lung cancer. We investigated whether pre-treatment tumor size (PTS) is predictive of progression-free survival (PFS) and tumor shrinkage in head and neck squamous cell carcinoma (HNSCC) patients treated with nivolumab. We retrospectively assessed 37 patients who had measurable tumor lesions. PTS and post-treatment tumor size were defined as the sum of the size in all measurable lesions. In univariate analysis, PTS below 42 mm, history of radiation therapy, and no use of cetuximab were significantly associated with longer PFS. Among them, small-PTS was an independent predictive factor for PFS in multivariate analysis (hazard ratio: 0.33, p = 0.022). In addition, significantly greater tumor shrinkage was observed for small-PTS than large-PTS (median: −10.0% vs. 23.1%, p = 0.033). PTS may impact the response to nivolumab in HNSCC patients.</description><identifier>ISSN: 0385-8146</identifier><identifier>EISSN: 1879-1476</identifier><identifier>DOI: 10.1016/j.anl.2020.01.003</identifier><identifier>PMID: 32035695</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Head and neck squamous cell carcinoma ; Nivolumab ; Predictive factor ; Tumor size</subject><ispartof>Auris, nasus, larynx, 2020-08, Vol.47 (4), p.650-657</ispartof><rights>2020</rights><rights>Copyright © 2020. Published by Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c443t-b518a1ee9a875dbf98a1f3b19efdb196551531f255cd1be50d6e1220c6cadff43</citedby><cites>FETCH-LOGICAL-c443t-b518a1ee9a875dbf98a1f3b19efdb196551531f255cd1be50d6e1220c6cadff43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0385814620300237$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32035695$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Inoue, Hiroto</creatorcontrib><creatorcontrib>Yokota, Tomoya</creatorcontrib><creatorcontrib>Hamauchi, Satoshi</creatorcontrib><creatorcontrib>Onozawa, Yusuke</creatorcontrib><creatorcontrib>Kawakami, Takeshi</creatorcontrib><creatorcontrib>Shirasu, Hiromichi</creatorcontrib><creatorcontrib>Notsu, Akifumi</creatorcontrib><creatorcontrib>Yasui, Hirofumi</creatorcontrib><creatorcontrib>Onitsuka, Tetsuro</creatorcontrib><title>Pre-treatment tumor size impacts on response to nivolumab in head and neck squamous cell carcinoma</title><title>Auris, nasus, larynx</title><addtitle>Auris Nasus Larynx</addtitle><description>Baseline tumor size has been reported to be predictive of immune checkpoint inhibitor efficacy in melanoma and lung cancer. We investigated whether pre-treatment tumor size (PTS) is predictive of progression-free survival (PFS) and tumor shrinkage in head and neck squamous cell carcinoma (HNSCC) patients treated with nivolumab. We retrospectively assessed 37 patients who had measurable tumor lesions. PTS and post-treatment tumor size were defined as the sum of the size in all measurable lesions. In univariate analysis, PTS below 42 mm, history of radiation therapy, and no use of cetuximab were significantly associated with longer PFS. Among them, small-PTS was an independent predictive factor for PFS in multivariate analysis (hazard ratio: 0.33, p = 0.022). In addition, significantly greater tumor shrinkage was observed for small-PTS than large-PTS (median: −10.0% vs. 23.1%, p = 0.033). PTS may impact the response to nivolumab in HNSCC patients.</description><subject>Head and neck squamous cell carcinoma</subject><subject>Nivolumab</subject><subject>Predictive factor</subject><subject>Tumor size</subject><issn>0385-8146</issn><issn>1879-1476</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kMFq3DAQhkVoSLabPEAuRcdc7Gosy2vTUwlNWlhoDu1ZyNKYaGtJG0kOJE9fLbvNsZcZBr75mfkIuQFWA4Pu865Wfq4b1rCaQc0YPyMr6DdDBe2m-0BWjPei6qHtLsnHlHasEBs-XJBL3jAuukGsyPgYscoRVXboM82LC5Em-4bUur3SOdHgacS0Dz4hzYF6-xLmxamRWk-fUBmqvKEe9R-anhflwpKoxnmmWkVtfXDqipxPak54fepr8vv-26-779X258OPu6_bSrctz9UooFeAOKh-I8w4DWWa-AgDTqbUTggQHKZGCG1gRMFMh9A0THdamWlq-ZrcHnP3MTwvmLJ0Nh1OUR7LVbLhgjMY2qYvKBxRHUNKESe5j9ap-CqByYNauZNFrTyolQxkEVd2Pp3il9Ghed_457IAX44AlidfLEaZtEWv0diIOksT7H_i_wKl6Irl</recordid><startdate>20200801</startdate><enddate>20200801</enddate><creator>Inoue, Hiroto</creator><creator>Yokota, Tomoya</creator><creator>Hamauchi, Satoshi</creator><creator>Onozawa, Yusuke</creator><creator>Kawakami, Takeshi</creator><creator>Shirasu, Hiromichi</creator><creator>Notsu, Akifumi</creator><creator>Yasui, Hirofumi</creator><creator>Onitsuka, Tetsuro</creator><general>Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20200801</creationdate><title>Pre-treatment tumor size impacts on response to nivolumab in head and neck squamous cell carcinoma</title><author>Inoue, Hiroto ; Yokota, Tomoya ; Hamauchi, Satoshi ; Onozawa, Yusuke ; Kawakami, Takeshi ; Shirasu, Hiromichi ; Notsu, Akifumi ; Yasui, Hirofumi ; Onitsuka, Tetsuro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c443t-b518a1ee9a875dbf98a1f3b19efdb196551531f255cd1be50d6e1220c6cadff43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Head and neck squamous cell carcinoma</topic><topic>Nivolumab</topic><topic>Predictive factor</topic><topic>Tumor size</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Inoue, Hiroto</creatorcontrib><creatorcontrib>Yokota, Tomoya</creatorcontrib><creatorcontrib>Hamauchi, Satoshi</creatorcontrib><creatorcontrib>Onozawa, Yusuke</creatorcontrib><creatorcontrib>Kawakami, Takeshi</creatorcontrib><creatorcontrib>Shirasu, Hiromichi</creatorcontrib><creatorcontrib>Notsu, Akifumi</creatorcontrib><creatorcontrib>Yasui, Hirofumi</creatorcontrib><creatorcontrib>Onitsuka, Tetsuro</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Auris, nasus, larynx</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Inoue, Hiroto</au><au>Yokota, Tomoya</au><au>Hamauchi, Satoshi</au><au>Onozawa, Yusuke</au><au>Kawakami, Takeshi</au><au>Shirasu, Hiromichi</au><au>Notsu, Akifumi</au><au>Yasui, Hirofumi</au><au>Onitsuka, Tetsuro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pre-treatment tumor size impacts on response to nivolumab in head and neck squamous cell carcinoma</atitle><jtitle>Auris, nasus, larynx</jtitle><addtitle>Auris Nasus Larynx</addtitle><date>2020-08-01</date><risdate>2020</risdate><volume>47</volume><issue>4</issue><spage>650</spage><epage>657</epage><pages>650-657</pages><issn>0385-8146</issn><eissn>1879-1476</eissn><abstract>Baseline tumor size has been reported to be predictive of immune checkpoint inhibitor efficacy in melanoma and lung cancer. We investigated whether pre-treatment tumor size (PTS) is predictive of progression-free survival (PFS) and tumor shrinkage in head and neck squamous cell carcinoma (HNSCC) patients treated with nivolumab. We retrospectively assessed 37 patients who had measurable tumor lesions. PTS and post-treatment tumor size were defined as the sum of the size in all measurable lesions. In univariate analysis, PTS below 42 mm, history of radiation therapy, and no use of cetuximab were significantly associated with longer PFS. Among them, small-PTS was an independent predictive factor for PFS in multivariate analysis (hazard ratio: 0.33, p = 0.022). In addition, significantly greater tumor shrinkage was observed for small-PTS than large-PTS (median: −10.0% vs. 23.1%, p = 0.033). PTS may impact the response to nivolumab in HNSCC patients.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>32035695</pmid><doi>10.1016/j.anl.2020.01.003</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0385-8146
ispartof Auris, nasus, larynx, 2020-08, Vol.47 (4), p.650-657
issn 0385-8146
1879-1476
language eng
recordid cdi_proquest_miscellaneous_2353019428
source Elsevier ScienceDirect Journals
subjects Head and neck squamous cell carcinoma
Nivolumab
Predictive factor
Tumor size
title Pre-treatment tumor size impacts on response to nivolumab in head and neck squamous cell carcinoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T08%3A30%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pre-treatment%20tumor%20size%20impacts%20on%20response%20to%20nivolumab%20in%20head%20and%20neck%20squamous%20cell%20carcinoma&rft.jtitle=Auris,%20nasus,%20larynx&rft.au=Inoue,%20Hiroto&rft.date=2020-08-01&rft.volume=47&rft.issue=4&rft.spage=650&rft.epage=657&rft.pages=650-657&rft.issn=0385-8146&rft.eissn=1879-1476&rft_id=info:doi/10.1016/j.anl.2020.01.003&rft_dat=%3Cproquest_cross%3E2353019428%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2353019428&rft_id=info:pmid/32035695&rft_els_id=S0385814620300237&rfr_iscdi=true